Supply of COVID-19 vaccines to China? Moderna CEO says capacity is available
Moderna Inc's MRNA CEO Stephane Bancel said the company has discussed with the Chinese government about providing COVID-19 vaccines, but no decision has been made. was taken, Reuters reported.
"We are open, we have the capacity," Bancel said, but declined to say whether Moderna had submitted its vaccine for approval in the country.
There is about a 20% chance that a "problematic" variant of the virus could emerge this winter, Bancel said, adding that was not his base case scenario .
Speaking in Tokyo, CEO Bancel said Moderna was considering building a factory in Japan to produce its vaccines, Nikkei Asia reported.
Related: Europe supports approval of Omicron-tailored COVID-19 vaccines.
He added that construction would begin immediately if the Japanese government signed a long-term agreement (say ten years). The location and other details remain undetermined.
Bancel said Moderna would like to build a factory in Japan, with centralized processes, including manufacturing, in a single facility. The plant would be able to produce vaccines against COVID, influenza and other vaccines, Bancel said.
The vaccine developed by Moderna for the omicron variant has already been approved in Japan. The bivalent vaccine, which is effective for both the conventional variant and the BA.1 omicron variant, will soon be available. Vaccines against BA.4 and BA.5, currently the most prevalent strains, are being prepared.
Japan's regulatory authority on Monday approved Moderna's omicron-targeting bivalent COVID-19 booster for adults.
Price Action: MRNA shares rose 1.39% to $133.12 in the pre-market session of the last check on Wednesday.
Photo via Wikimedia Commons
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Moderna Inc's MRNA CEO Stephane Bancel said the company has discussed with the Chinese government about providing COVID-19 vaccines, but no decision has been made. was taken, Reuters reported.
"We are open, we have the capacity," Bancel said, but declined to say whether Moderna had submitted its vaccine for approval in the country.
There is about a 20% chance that a "problematic" variant of the virus could emerge this winter, Bancel said, adding that was not his base case scenario .
Speaking in Tokyo, CEO Bancel said Moderna was considering building a factory in Japan to produce its vaccines, Nikkei Asia reported.
Related: Europe supports approval of Omicron-tailored COVID-19 vaccines.
He added that construction would begin immediately if the Japanese government signed a long-term agreement (say ten years). The location and other details remain undetermined.
Bancel said Moderna would like to build a factory in Japan, with centralized processes, including manufacturing, in a single facility. The plant would be able to produce vaccines against COVID, influenza and other vaccines, Bancel said.
The vaccine developed by Moderna for the omicron variant has already been approved in Japan. The bivalent vaccine, which is effective for both the conventional variant and the BA.1 omicron variant, will soon be available. Vaccines against BA.4 and BA.5, currently the most prevalent strains, are being prepared.
Japan's regulatory authority on Monday approved Moderna's omicron-targeting bivalent COVID-19 booster for adults.
Price Action: MRNA shares rose 1.39% to $133.12 in the pre-market session of the last check on Wednesday.
Photo via Wikimedia Commons
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
What's Your Reaction?
